TNFSF10 and breast carcinoma: In order to establish the extent to which c-FLIP might broaden the specificity of TRAIL-induced cytotoxicity, we wanted to directly compare the relative sensitivity of different breast cancer subtypes to the combined effects of c-FLIP inhibition and TRAIL treatment.